This is a multi-centre, randomised, double-blinded, active-controlled, 2-way cross over trial
to assess the effects of once daily administration of orally inhaled tiotropium + olodaterol
FDC or tiotropium (both delivered by the RESPIMAT Inhaler) on pulmonary function (lung
hyperinflation), exercise capacity (6-minute walk distance) and physical activities after 6
weeks of treatment in Japanese patients with Chronic Obstructive Pulmonary Disease.